Novel Adenylyl Cyclase 1 Inhibitors for Chronic Pain and Opioid Dependence
- Summary
- Researchers at Purdue University have developed compounds that may provide an effective method of treatment for chronic and inflammatory pain by inhibiting selective adenylyl cyclases, especially adenylyl cyclase 1. These compounds may also prevent and/or reduce opioid dependence.
- Technology Benefits
- Chronic and inflammatory pain reliefNon-opioidNon-addictivePossibly treat opioid dependence
- Technology Application
- Pain treatmentOpioid dependence treatment option
- Detailed Technology Description
- Val J. WattsVal J. Watts LabPurdue Medicinal Chemistry and Molecular Pharmacology
- Countries
- United States
- Application No.
- None
- *Abstract
-
None
- *Background
- According to a 2012 study by the American Pain Society, the annual cost of chronic pain in the United States is as high as $635 million, impacting more than 100 million people. According to the Centers for Disease Control and Prevention (CDC), 91 people die in the U.S. every day from an opioid overdose. Chronic and inflammatory pain are treated with antidepressants, anticonvulsants, and/or opioids. The use of opioids often leads to opioid dependence, which is treated with opioid substitutes such as methadone, buprenorphine, or opioid antagonists. There is a need for a treatment option for chronic and inflammatory pain that provides effective pain relief as well as eliminates opioid addiction and dependence.
- *IP Issue Date
- None
- *IP Type
- Provisional
- *Stage of Development
- Bench testing performed
- *Web Links
- Purdue Office of Technology CommercializationPurdue Innovation and EntrepreneurshipVal J. WattsVal J. Watts LabPurdue Medicinal Chemistry and Molecular Pharmacology
- Country/Region
- USA
For more information, please click Here
